Table 2.
Comparison of clinical and laboratory features between ZNF300 hypermethylated and non-hypermethylated AML patients.
| Patient’s features | Non-hypermethylated (n = 63) | Hypermethylated (n = 97) | P value |
|---|---|---|---|
| Sex, male/female | 31/32 | 65/32 | 0.032 |
| Median age, years (range) | 57 (18–85) | 55 (18–86) | 0.522 |
| Median WBC, ×109/L (range) | 11.75 (0.9–528.0) | 18.7 (0.3–201.0) | 0.261 |
| Median hemoglobin, g/L (range) | 83 (42–135) | 76 (32–144) | 0.273 |
| Median platelets, ×109/L (range) | 53 (3–447) | 32 (5–415) | 0.002 |
| Median BM blasts, % (range) | 56.64 (5.5*–97.5) | 49.25 (1.0*–99.0) | 0.881 |
| FAB classifications | 0.670 | ||
| M0 | 0 | 2 | |
| M1 | 2 | 8 | |
| M2 | 23 | 39 | |
| M3 | 14 | 15 | |
| M4 | 13 | 17 | |
| M5 | 8 | 11 | |
| M6 | 3 | 3 | |
| No data | 0 | 2 | |
| Karyotypes | 0.366 | ||
| normal | 25 | 46 | |
| t(8;21) | 2 | 9 | |
| inv(16) | 0 | 1 | |
| t(15;17) | 14 | 13 | |
| +8 | 3 | 2 | |
| −7/7q− | 0 | 1 | |
| t(9;22) | 1 | 1 | |
| 11q23 | 0 | 2 | |
| complex | 10 | 7 | |
| others | 4 | 9 | |
| No data | 4 | 6 | |
| Gene mutations | |||
| CEBPA (+/−) | 2/53 | 10/61 | 0.066 |
| NPM1 (+/−) | 5/50 | 9/62 | 0.580 |
| FLT3-ITD (+/−) | 4/51 | 7/64 | 0.755 |
| C-KIT (+/−) | 3/52 | 4/67 | 1.000 |
| N/K-RAS (+/−) | 4/51 | 8/63 | 0.549 |
| IDH1/2 (+/−) | 3/52 | 2/69 | 0.652 |
| DNMT3A (+/−) | 4/51 | 4/67 | 0.728 |
| U2AF1 (+/−) | 0/55 | 3/68 | 0.256 |
| SRSF2 (+/−) | 2/53 | 2/69 | 1.000 |
| SETBP1 (+/−) | 0/55 | 2/69 | 0.504 |
| CR, total AML (+/−) | 31/25 | 30/50 | 0.054 |
| CR, non-M3 AML (+/−) | 20/23 | 20/48 | 0.073 |
| CR, CN-AML (+/−) | 12/8 | 12/27 | 0.049 |
WBC white blood cells, BM bone marrow, FAB French-American-British classification, CR complete remission.
*Patients’ blasts less than 20% with t(15;17) cytogenetic aberrations.